ArticleTranslational stroke research2026
Salvaging the No-Reflow Zone: Intra-arterial Cranial Bone-Derived MSCs Restore Neurovascular Integrity After Stroke.
Article in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Successful macrovascular recanalization does not always translate into functional recovery, in part because early post-reperfusion injury can drive infarct expansion. Here, we investigated whether hyperacute intra-arterial transplantation of human cranial bone-derived mesenchymal stem cells (hcMSCs) immediately after reperfusion improves functional recovery after ischemic stroke. Transient middle cerebral artery occlusion was induced in adult rats, followed by intra-arterial administration of hcMSCs or vehicle immediately after reperfusion. Neurological and motor pathway recovery were assessed longitudinally using the modified neurological severity score and transcranial motor-evoked potentials. During the acute phase, molecular and histological analyses of peri-infarct tissue were performed and the transcriptomic profiles of hcMSCs compared with those of human bone marrow-derived mesenchymal stem cells (hbMSCs). Hyperacute intra-arterial hcMSC transplantation resulted in significantly faster neurological recovery compared with controls, accompanied by enhanced electrophysiological recovery of motor pathway function. These functional improvements were associated with preservation of neuronal structural integrity in the peri-infarct cortex, attenuation of inflammatory cytokines and apoptosis activity, and vascular endothelial growth factor upregulation. Further, transcriptomic analysis revealed that hcMSCs are enriched in neurotrophic, angiogenic, and immunoregulatory factors, providing a biological support for the observed therapeutic effects. Hyperacute intra-arterial hcMSC delivery immediately after reperfusion promotes functional and electrophysiological recovery in an experimental reperfusion model, likely through early modulation of inflammatory and apoptotic responses in the peri-infarct tissue. These findings support further investigation of hcMSC therapy as a biologically protective adjunctive strategy in the immediate post-recanalization setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.